Liposome and immunoliposome formulations of two vinca alkaloids, vincristine and vinblastine, were prepared using intraliposomal triethylammonium sucroseoctasulfate and examined for their ability to stabilize the drug for targeted drug delivery in vivo.
The pharmacokinetics of both the encapsulated drug (vincristine or vinblastine) and liposomal carrier were examined in Sprague Dawley rats, and the in vivo drug release rates determined. Anti-HER2 immunoliposomal vincristine was prepared from a human anti-HER2/neu scFv and studied for targeted cytotoxic activity in cell culture, and antitumor efficacy in vivo.
Nanoliposome formulations of vincristine and vinblastine demonstrated similar pharmacokinetic profiles for the liposomal carrier, but increased clearance for liposome encapsulated vinblastine (t1/2 = 9.7 h) relative to vincristine (t1/2 = 18.5 h). Immunoliposome formulations of vincristine targeted to HER2 using an anti-HER2 scFv antibody fragment displayed a marked enhancement in cytotoxicity when compared to non-targeted liposomal vincristine control; 63- or 253-fold for BT474 and SKBR3 breast cancer cells, respectively. Target-specific activity was also demonstrated in HER2-overexpressing human tumor xenografts, where the HER2-targeted formulation was significantly more efficacious than either free vincristine or non-targeted liposomal vincristine.
These results demonstrate that active targeting of solid tumors with liposomal formulations of vincristine is possible when the resulting immunoliposomes are sufficiently stabilized.
Bartlett GR (1959) Phosphorous assay in column chromatography. J Biol Chem 234:466–468 PubMed
Cheng S, Evans WK, Stys-Norman D, Shepherd FA (2007) Chemotherapy for relapsed small cell lung cancer: a systematic review and practice guideline. J Thorac Oncol 2:348–354 PubMed
Cullis PR, Hope MJ, Bally MB, Madden TD, Mayer LD, Fenske DB (1997) Influence of pH gradients on the transbilayer transport of drugs, lipids, peptides and metal ions into large unilamellar vesicles. Biochim Biophys Acta 1331:187–211 PubMed
Drummond DC, Meyer OM, Hong K, Kirpotin DB, Papahadjopoulos D (1999) Optimizing liposomes for delivery of chemotherapeutic agents to solid tumors. Pharmacol Rev 51:691–743 PubMed
Gelmon KA, Tolcher A, Diab AR, Bally MB, Embree L, Hudon N, Dedhar C, Ayers D, Eisen A, Melosky B, Burge C, Logan P, Mayer LD (1999) Phase I study of liposomal vincristine. J Clin Oncol 17:697–705 PubMed
Jackson DV Jr, Bender RA (1979) Cytotoxic thresholds of vincristine in a murine and a human leukemia cell line in vitro. Cancer Res 39:4346–4349 PubMed
Laverman P, Brouwers AH, Dams ETM, Oyen WJG, Storm G, Van Rooigen N, Corstens FHM, Boerman OC (2000) Preclinical and clincal evidence for disappearance of long-circulating characteristics of polyethylene glycol liposomes at low lipid dose. J Pharmacol Exp Ther 293:996–1001 PubMed
Legha SS (1997) Durable complete responses in metastatic melanoma treated with interleukin-2 in combination with interferon alpha and chemotherapy. Semin Oncol 24:S39–S43 PubMed
Maeda H, Matsumura Y (1989) Tumoritropic and lymphotropic principles of macromolecular drugs. CRC Crit Rev Therap Drug Carrier System 6:193–210
Mayer LD, Bally MB, Loughrey H, Masin D, Cullis PR (1990) Liposomal vincristine preparations which exhibit decreased drug toxicity and increased activity against murine L1210 and P388 tumors. Cancer Res 50:575–579 PubMed
Nellis DF, Ekstrom DL, Kirpotin DB, Zhu J, Andersson R, Broadt TL, Ouellette TF, Perkins SC, Roach JM, Drummond DC, Hong K, Marks JD, Park JW, Giardina SL (2005) Preclinical manufacture of an anti-HER2 scFv-PEG-DSPE, liposome-inserting conjugate. 1. Gram-scale production and purification. Biotechnol Prog 21:205–220 PubMedCrossRef
Nellis DF, Giardina SL, Janini GM, Shenoy SR, Marks JD, Tsai R, Drummond DC, Hong K, Park JW, Ouellette TF, Perkins SC, Kirpotin DB (2005) Preclinical manufacture of anti-HER2 liposome-inserting, scFv-PEG-lipid conjugate. 2. Conjugate micelle identity, purity, stability, and potency analysis. Biotechnol Prog 21:221–232 PubMedCrossRef
Park JW, Hong K, Kirpotin DB, Colbern G, Shalaby R, Baselga J, Shao Y, Nielsen UB, Marks JD, Moore D, Papahadjopoulos D, Benz CC (2002) Anti-HER2 immunoliposomes: enhanced efficacy attributable to targeted delivery. Clin Cancer Res 8:1172–1181 PubMed
Pinkerton CR, Blanc Vincent MP, Bergeron C, Fervers B, Philip T (2000) Induction chemotherapy in metastatic neuroblastoma–does dose influence response? A critical review of published data standards, options and recommendations (SOR) project of the National Federation of French Cancer Centres (FNCLCC). Eur J Cancer 36:1808–1815 PubMedCrossRef
Rowinsky E, Donehower R (1996) Antimicrotubule Agents. In: Chabner B, Longo D (eds) Cancer chemotherapy and biotherapy: principles and practice. Lippincott-Raven Publishers, Philadelphia, pp 263–296
Semple SC, Leone R, Wang J, Leng EC, Klimuk SK, Eisenhardt ML, Yuan ZN, Edwards K, Maurer N, Hope MJ, Cullis PR, Ahkong QF (2005) Optimization and characterization of a sphingomyelin/cholesterol liposome formulation of vinorelbine with promising antitumor activity. J Pharm Sci 94:1024–1038 PubMedCrossRef
Webb MS, Harasym TO, Masin D, Bally MB, Mayer LD (1995) Sphingomyelin-cholesterol liposomes significantly enhance the pharmacokinetic and therapeutic properties of vincristine in murine and human tumour models. Br J Cancer 72:896–904 PubMed
Working PK, Dayan AD (1996) Pharmacological-toxicological expert report—Caelyx(TM) (Stealth(R) liposomal doxorubicin HCl)—Foreword. Hum Exp Toxicol 15:751–785 PubMed
- Characterization of highly stable liposomal and immunoliposomal formulations of vincristine and vinblastine
Charles O. Noble
Mark E. Hayes
James D. Marks
John W. Park
Christopher C. Benz
Dmitri B. Kirpotin
Daryl C. Drummond
Neu im Fachgebiet Onkologie
Mail Icon II